BioCentury | Aug 18, 2018
Regulation

Pediatric push

...more of the following targets: synaptic vesicle protein (SV2A), sodium channels, calcium channels, AMPA glutamate receptor (GRIA; GLUR...
BioCentury | Jul 26, 2018
Translation in Brief

A plasticity problem

...which is under review. Elizabeth S. Eaton, Staff Writer University of Bordeaux Beta amyloid Calcium calmodulin-dependent protein kinase II (CAMK2) AMPA receptor...
BioCentury | Jun 21, 2018
Emerging Company Profile

Getting past PTSD

Neurovation Labs Inc. is developing a GRIA1-targeting tracer and a small molecule therapy that could provide an objective diagnosis of PTSD and treat the underlying disease instead of just its symptoms. Post-traumatic stress disorder (PTSD)...
BioCentury | May 5, 2018
Product Development

Rebuilding Biogen’s brain

...testing; Targets: ABCC8 - ATP-binding cassette sub-family C member 8 (SUR1); AMPA receptor - AMPA glutamate receptor (GRIA; GLUR...
...and up to $515 million in milestones. The positive allosteric modulator (PAM) of AMPA glutamate receptor (GRIA; GLUR...
...schizophrenia. Coming from Pfizer, Ehlers has a history with the program; he also worked on AMPA receptor...
BioCentury | May 4, 2018
Company News

Accelerator launches Proniras to develop anticonvulsant

...that acquisition. Proniras Corp., Seattle, Wash. Business: Neurology Sandi Wong tezampanel (LY-293,558) Accelerator Life Science Partners Eli Lilly and Co. Proniras AMPA glutamate receptor (GRIA) (GLUR) Glutamate...
BioCentury | May 3, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: April 2018

...receptor kainate type subunit 1 (GluK1; GRIK1; GLUR5) Preclinical studies suggest the dual GluK1/AMPA glutamate receptor (GRIA; GLUR...
BioCentury | Apr 27, 2018
Company News

Accelerator launches Proniras to develop anticonvulsant

Accelerator Life Science Partners (Seattle, Wash.) launched newco Proniras Corp. (Seattle, Wash.) to develop tezampanel (LY293558) to treat nerve agent-induced seizures. Proniras has received an $89.5 million award from HHS’s Biomedical Advanced Research and Development...
BioCentury | Apr 24, 2018
Company News

Biogen looks to ex-U.S. markets for growth

...formerly PF-04958242) from Pfizer Inc. (NYSE:PFE). Biogen plans to develop the Phase II AMPA glutamate receptor (GRIA; GLUR...
BioCentury | Mar 16, 2018
Company News

Biogen scoops up neuropsychiatry candidate from Pfizer

...cognitive impairment associated with schizophrenia. PF-04958242 is a positive allosteric modulator (PAM) of AMPA glutamate receptor (GRIA; GLUR...
...Pfizer Inc. (NYSE:PFE), New York, N.Y. Biogen Inc. (NASDAQ:BIIB), Cambridge, Mass. Business: Neurology Sandi Wong PF-04958242 Biogen Inc. Pfizer Inc. AMPA receptor...
BioCentury | Mar 12, 2018
Company News

Biogen scoops up neuropsychiatry candidate from Pfizer

...cognitive impairment associated with schizophrenia. PF-04958242 is a positive allosteric modulator (PAM) of AMPA glutamate receptor (GRIA; GLUR...
...deal to close in 2Q18. The biotech slipped $6.20 to $279.90 on Monday. Sandi Wong Biogen Inc. Pfizer Inc. AMPA glutamate receptor PF-04958242...
Items per page:
1 - 10 of 210